Comparison of Minimum Viable Scenario MVS and Full

Comparison of Minimum Viable Scenario (MVS) and Full Value Scenario (FVS) MVS FVS Total Global NPV ($M) $331 $1, 774 Total Global Women using Ovulona 12. 2 55. 3 total global net present value (detailed US model plus rest of world estimate) millions of women using Ovulona GLOBALLY by the 10 th year Model Summary (US Only) NPV ($M) $102 Investment ($M) $731 $22. 6 $19. 5 10 -year GS ($M) $5, 469 $1, 088 Initial Sales (month) US-only Profitability: 1 st positive Cash Flow (month) 16 16 33 32 NPAT/GS @10 YR (%) 48. 8% 38. 9% Gross-to-Net @10 YR (%) Women using Ovulona @10 YR (M) Total Women in Target (M) % of Women Using Ovulona @10 YR Total Doctors Using Ovulona @10 YR Earnings/Doctor @10 YR ($/year) 82. 2% 3. 67 88. 6% 13. 8 62. 2 16. 6 22. 1% 6, 810 $4, 760 22. 2% 22, 558 $8, 817 net present value, calculated based on the NPAT (net profit after taxes) minus the NPV of the investments the amount of money needed to execute this model 10 year cumulative gross sales in millions the first month that the business generates revenue the first month that the business becomes profitable the percentage of our gross sales converted into profit the impact of discounts and returns on gross sales (doctors and patients referring get a discount credit; returns are also applied millions of women using Ovulona by the 10 th year millions of women in target for this indication % of the target women using Ovulona by the end of 10 years cumulative number of doctors using Ovulona by the 10 th year the annual average incentive payments doctors receive total number of full time